PRODUCT INFORMATION



Fosamprenavir (calcium salt)

Item No. 21609

CAS Registry No.:	226700-81-8	
Formal Name:	N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl]	
	(2-methylpropyl)amino]-1-(phenylmethyl)-	
	2-(phosphonooxy)propyl]-carbamic	
	acid, (3S)-tetrahydro-3-furanyl ester,	
	monocalcium salt	
Synonym:	GW 433908G	\downarrow \downarrow \land $\overset{\vee}{s}$ \land
MF:	$C_{25}H_{34}N_3O_9PS \bullet Ca$	ρ^{-} N^{-} γ^{-} N^{-} γ^{-}
FW:	623.7	
Purity:	≥98%	
,		
UV/Vis.:	λ_{max} : 268 nm	└O´ O- • Ca²+
Supplied as:	A crystalline solid	I
Storage:	-20°C	
Stability:	≥4 years	
Information memory to the mend out and if a time. Database if a mark time memory is a memory if a data a family		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fosamprenavir (calcium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the fosamprenavir (calcium salt) in the solvent of choice, which should be purged with an inert gas. Fosamprenavir (calcium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of fosamprenavir (calcium salt) in ethanol is approximately 2 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Fosamprenavir (calcium salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, fosamprenavir (calcium salt) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Fosamprenavir (calcium salt) has a solubility of approximately 0.11 mg/ml in a 1:8 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Fosamprenavir is a prodrug form of the HIV-1 protease inhibitor amprenavir (Item No. 15369).¹ It is converted to amprenavir by alkaline phosphatase in the intestinal epithelium. Formulations containing fosamprenavir have been used in the treatment of HIV infections.

Reference

1. Wire, M.B., Shelton, M.J., and Studenberg, S. Fosamprenavir: Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45(2), 137-168 (2006).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM